Contact
searchSearch
HMP Global
Login

Biomarker Testing Videos

Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Nicholas Robert, MD
Videos
Identifying Predictors of Biomarker Testing in Metastatic Non-Small Cell Lung Cancer
07/05/2022
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses...
07/05/2022
Journal of Clinical Pathways
Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
04/27/2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS,...
04/27/2021
Journal of Clinical Pathways
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use